Overview

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.
Phase:
Phase 1
Details
Lead Sponsor:
NeuroSearch A/S
Treatments:
Levodopa